SCHEMBL214270

SCHEMBL214270

C[CH]c1cccc(F)c1[N+](=O)[O-]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
TSHR P16473 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 3/20 0.38
LMNA P02545 2/20 0.38
NTSR1 P30989 1/20 0.38
NPC1 O15118 1/20 0.38
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.36
ERN1 O75460 2/20 0.36
GPR35 Q9HC97 1/20 0.35
NFE2L2 Q16236 2/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
CES2 O00748 1/20 0.33
CES1 P23141 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL103025 0.83 ERN1 (0.50) ALDH1A1TDP1TSHRMEN1KMT2A
SCHEMBL29952992 0.83 ERN1 (0.50) ALDH1A1TDP1TSHRMEN1KMT2A
SCHEMBL16952733 0.81 ALDH1A1 (0.39) ALDH1A1TDP1TSHRMEN1KMT2A
SCHEMBL31023003 0.81 ALDH1A1 (0.39) ALDH1A1TDP1TSHRMEN1KMT2A
SCHEMBL16950618 0.81 MEN1 (0.45) ALDH1A1TDP1TSHRMEN1KMT2A
SCHEMBL240574 0.80 TDP1 (0.52) ALDH1A1TDP1TSHRMAPTLMNA
SCHEMBL212006 0.78 ALDH1A1 (0.35) ALDH1A1TDP1TSHRMEN1KMT2A
SCHEMBL29074272 0.76 NFE2L2 (0.58) ALDH1A1MEN1KMT2AMAPTLMNA
SCHEMBL27140785 0.75 MAPT (0.58) ALDH1A1TDP1MEN1KMT2AMAPT
SCHEMBL30159186 0.75 ALDH1A1 (0.72) ALDH1A1TDP1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264612-A1 MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA UNIV COLUMBIA (US) 2016-09-15 US claimed
US-20130096015-A1 Massive Parallel Method For Decoding DNA And RNA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2013-04-18 US claimed
US-7345159-B2 Massive parallel method for decoding DNA and RNA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2008-03-18 US claimed
EP-1790736-A2 Massive parallel method for decoding DNA and RNA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2007-05-30 EP claimed
EP-1337541-B1 Massive parallel method for decoding DNA and RNA UNIV COLUMBIA (US) 2007-03-07 EP claimed
US-20040185466-A1 to detect single nucleotide polymorphisms, genetic mutation, gene expression, forensic identification, disease association, DNA/genomic sequencing and translation/transcription analysis; solid phase synthesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK. 2004-09-23 US claimed
EP-1337541-A4 MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA UNIV COLUMBIA (US) 2004-07-14 EP claimed
JP-2004510433-A 2004-04-08 JP claimed
US-6664079-B2 Sequencing nucleic acid; obtain nucleotide sequences, incubate in reaction mixture, apply to solid support, determine nucleotide sequences THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2003-12-16 US claimed
EP-1337541-A2 Massive parallel method for decoding DNA and RNA The Trustees of Columbia University in the City of New York (US) 2003-08-27 EP claimed
US-20020102586-A1 Sequencing nucleic acid; obtain nucleotide sequences, incubate in reaction mixture, apply to solid support, determine nucleotide sequences NATIONAL SCIENCE FOUNDATION 2002-08-01 US claimed
WO-2002029003-A2 MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2002-04-11 WO claimed
US-11940413-B2 Methods and devices for sequencing nucleic acids in smaller batches IsoPlexis Corporation (US) 2024-03-26 US disclosed
US-20240076731-A1 METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES QIAGEN SCIENCES, LLC 2024-03-07 US disclosed
US-20240060128-A1 METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES QIAGEN WALTHAM, INC. 2024-02-22 US disclosed
US-20230407384-A1 METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES QIAGEN WALTHAM, INC. 2023-12-21 US disclosed
US-6664079-B2 Sequencing nucleic acid; obtain nucleotide sequences, incubate in reaction mixture, apply to solid support, determine nucleotide sequences THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2003-12-16 US disclosed
EP-1337541-A2 Massive parallel method for decoding DNA and RNA The Trustees of Columbia University in the City of New York (US) 2003-08-27 EP disclosed
US-20020102586-A1 Sequencing nucleic acid; obtain nucleotide sequences, incubate in reaction mixture, apply to solid support, determine nucleotide sequences NATIONAL SCIENCE FOUNDATION 2002-08-01 US disclosed
WO-2002029003-A2 MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264612-A1 MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA RNGTT, NSUN2, RNMT ALDH1A1 3815/4885TDP1 299/4885TSHR 3024/4885
US-20240076731-A1 METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES NT5C2, NOP2, NT5C3B ALDH1A1 4837/4885TDP1 116/4885TSHR 3450/4885
US-20230407384-A1 METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES NT5C2, NOP2, NT5C3B ALDH1A1 4837/4885TDP1 116/4885TSHR 3450/4885
US-20240060128-A1 METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES NT5C2, NOP2, NT5C3B ALDH1A1 4837/4885TDP1 116/4885TSHR 3450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.